104 In the index

Tabimorelin TABI

An oral compound studied in early human trials for boosting growth hormone release. Development was stopped after trials showed the body quickly became less responsive to it with repeated use, limiting how useful it would actually be.

Also known as NN703, L51CBE03KF, tabimorelina, tabimoreline, NNC-26-0703, tabimorelinum, RefChem:187089, Tabimorelin [INN]

Effects Build muscle

Routes Oral

Legal status Research chemical

WADA Banned at all times

3D Molecular Structure of C₃₂H₄₀N₄O₃

Drag to rotate · scroll to zoom

Chemistry

Formula: C32H40N4O3
Molar mass: 528.7
CAS: 193079-69-5
PubChem CID: 9810101
IUPAC name: (E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(2R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
InChIKey: WURGZWOTGMLDJP-ZCYANPAGSA-N

Reported dosing

Limited data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (development discontinued)

Reported range Early trial doses not widely published

Route Oral

Frequency Not established

Duration Not established

An oral ghrelin-mimetic growth-hormone secretagogue whose clinical development was discontinued; essentially no human dosing data exists publicly.

Where this comes from Early-stage/preclinical pharma data only

Human data for this compound is limited. Read the figures above as a record of reported use rather than established dosing.